"versionIdentifier","uuid:ID","rationale","id","instanceType"
"2","edc9cfb1-8daf-4cca-bdda-cb49c59a97b1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","StudyVersion"
